CSL Names Deborah Waterhouse as Its First Woman Chief Executive

One of Australia's largest companies has a new leader, and she brings almost three decades of global healthcare experience with her.

CSL, the Melbourne based biotechnology group, announced on October 21 that Deborah Waterhouse will become its Chief Executive Officer and Managing Director from 1 February 2027. Reuters reported that she will be the first woman to lead the company in its history.

Who Deborah Waterhouse is

Waterhouse has been Chief Executive Officer of ViiV Healthcare since 2017. ViiV is the specialist HIV company majority owned by GSK, and she also serves as President of GSK Global Health.

According to CSL, ViiV recorded sales of £7.7 billion in GSK's 2025 financial year. That makes the business one of the most significant in the global fight against HIV, and it gives Waterhouse experience running a large, research driven company with patients around the world.

Her career at GSK spans many roles and markets. CSL noted that she served as General Manager of GSK's Australia and New Zealand business from 2008 to 2012, and that she held senior positions in the company's United States vaccines and primary care businesses.

A unanimous board decision

CSL said the board's decision was unanimous. Chair Dr Brian McNamee made the announcement on behalf of the board, closing a search that began after the company moved to an interim leadership arrangement.

Her earlier years running GSK in Australia and New Zealand give her a familiar starting point at a company with deep roots in Melbourne. She knows the local market, the regulators and the health system, even though most of her recent work has been global.

Waterhouse will remain based in the United Kingdom. That choice reflects how international CSL has become, with most of its revenue now earned outside Australia.

The road to February

Until Waterhouse takes over, Gordon Naylor will continue as interim Chief Executive Officer. CSL said he will keep leading the business through the transition period.

The company also disclosed key terms of her appointment, including a base salary of £1.5 million. As is standard for listed companies in Australia, the details were shared with the market on the day of the announcement.

For investors and employees, a clear start date brings some certainty. The next few months will give Waterhouse time to finish her work at ViiV and prepare for a company with a different structure and a broad portfolio.

What CSL does

CSL is best known for three businesses. CSL Behring makes therapies from human plasma for people with rare and serious diseases. CSL Seqirus is one of the world's largest makers of influenza vaccines. CSL Vifor works on treatments for iron deficiency and kidney disease.

That mix makes the CEO role demanding. The leader must balance large manufacturing operations, a long research pipeline and close relationships with health systems and regulators in many countries.

A milestone for women in healthcare

Women remain a minority among the chief executives of the world's largest listed companies, and healthcare is no exception. When a company of CSL's size appoints its first woman CEO, it sends a signal to the many women building careers in science, medicine and business.

Waterhouse's path also shows the value of broad experience. She has worked across vaccines, primary care, HIV medicine and global health, and she has led teams on more than one continent. That kind of range is exactly what large boards look for when they choose a leader for a global company.

Waterhouse will step into the role on 1 February 2027. Her early priorities have not yet been set out in detail, and CSL is expected to share more as her start date approaches.

For now, the appointment marks a new chapter for one of Australia's best known companies and a notable moment for women in healthcare leadership.